Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers

NCT06171971 | Unknown

• 1 other identifier: 8661
• Study Type: observational
• Target: 230
• Locations: 1 country
• Sites: 1

Brief Summary

Pediatric solid tumors with an unfavorable prognosis remain a public health issue due to their morbidity and mortality and their rapidly evolving profile. They are defined by an expected overall survival of \< 30%. Progress has been made in genomic medicine with existing recommendations for the adult population, with the objective of personalized medicine. Recommendations for the pediatric population are still under consideration

Conditions

Pediatric Solid Tumors

Keywords

Pediatric solid tumors; BROAD GENOMIC STUDIES; SOLID CANCERS; Genomic medicine

Outcome Measures

Primary Outcomes (1)

• Retrospective description of the clinical and therapeutic impact of the systematic performance of molecular analyzes on solid tumors

  The aim of this retrospective study is to improve and harmonize international practices

  up to 12 months

Eligibility Criteria

• Age: 1 Year - 22 Years
• Sex: all
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Patients of pediatric age up to 22 years included at the time of molecular analysis

You may qualify if:

• Patients of pediatric age up to 22 years included at the time of molecular analysis
• Histological carcinological diagnosis performed at HUS
• Carcinological follow-up performed at HUS
• Patients with a solid tumor of unfavorable prognosis, refractory or in relapse
• Molecular analysis performed on tumor or blood samples
• Adult patients who do not object to the re-use of their personal data for medical research purposes
• Minor patients and their parents who do not object to the re-use of their personal data for scientific research purposes.
• Molecular biology results not usable due to poor sample quality or insufficient genetic material
• Patients who have expressed their opposition to participate in the study
• Parental authority holders who have expressed their opposition to participate in the study

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service d'onco-hématologie pédiatrique - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

Central Study Contacts

Natacha ENTZ-WERLE, MD, PhD

CONTACT

33 3.88.12.87.94; natacha.entz-werle@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 6, 2022
• First Posted: December 15, 2023
• Study Start: June 20, 2022
• Primary Completion: December 1, 2023
• Study Completion: December 1, 2023
• Last Updated: December 15, 2023

Record last verified: 2023-12

Locations

FR (1)